(Q33339625)

25 July 2017

title

Administration of abciximab to patients receiving tirofiban or eptifibatide: effect on platelet function (English)

1 reference

25 July 2017

E I Lev

1

1 reference

25 July 2017

J I Osende

2

1 reference

25 July 2017

M F Richard

3

1 reference

25 July 2017

J A Robbins

4

1 reference

25 July 2017

J A Delfin

5

1 reference

25 July 2017

O Rodriguez

6

1 reference

25 July 2017

S K Sharma

7

1 reference

25 July 2017

T Jayasundera

8

1 reference

25 July 2017

J J Badimon

9

1 reference

25 July 2017

J D Marmur

10

1 reference

25 July 2017

language of work or name

English

0 references

publication date

1 March 2001

1 reference

Journal of the American College of Cardiology

25 July 2017

published in

1 reference

25 July 2017

volume

37

1 reference

25 July 2017

issue

3

1 reference

25 July 2017

page(s)

847-855

1 reference

Are we mortgaging the medical profession?

25 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901181-5

7 January 2021

The pathogenesis of atherosclerosis: a perspective for the 1990s

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901181-5

7 January 2021

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901181-5

7 January 2021

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901181-5

7 January 2021

Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901181-5

7 January 2021

Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901181-5

7 January 2021

Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901181-5

7 January 2021

Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901181-5

7 January 2021

Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901181-5

7 January 2021

Platelet glycoprotein IIb/IIIa antagonists. What are the relevant issues concerning their pharmacology and clinical use?

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901181-5

7 January 2021

Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901181-5

7 January 2021

Cone and plate(let) analyzer: monitoring glycoprotein IIb/IIIa antagonists and von Willebrand disease replacement therapy by testing platelet deposition under flow conditions.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901181-5

7 January 2021

Quantifying GPIIb/IIIa receptor binding using 2 monoclonal antibodies: discriminating abciximab and small molecular weight antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901181-5

7 January 2021

Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901181-5

7 January 2021

Differential dose-response to oral xemilofiban after antecedent intravenous abciximab. Administration for complex coronary intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901181-5

7 January 2021

Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: Implications for inhibition of the internal pool of GPIIb/IIIa receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901181-5

7 January 2021

Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901181-5

7 January 2021

10.1016/S0735-1097(00)01181-5

Identifiers

DOI

1 reference

25 July 2017

1 reference